Survival Outcomes Post-secondary Cytoreduction in Peritoneal Metastatic Cases from Ovarian Cancer: A Single Institute Study
Ovarian cancer remains the most lethal gynecological malignancy, with approximately 200,000 new cases and 100,000 deaths reported globally each year. This study aimed to evaluate the impact of secondary cytoreductive surgery (CRS), with or without hyperthermic intraperitoneal chemotherapy (HIPEC), on survival in patients with peritoneal metastatic ovarian cancer. A retrospective-analysis was performed for patients treated with secondary-cytoreduction at the St. George Peritonectomy Unit between 1997 and December 2024. A total of 66 cases were identified from a prospective departmental database. Patients were stratified based on Peritoneal Carcinomatosis Index (PCI) into two groups: PCI <20 and PCI ≥20. Survival outcomes and perioperative variables were analyzed. Multivariate Cox regression revealed that morbidity grade significantly impacted overall survival [odds ratio (OR)=1.641, PCI is an independent prognostic indicator in patients with advanced ovarian cancer receiving secondary cytoreduction surgery. The addition of HIPEC offers a significant survival advantage, particularly in patients with high PCI, when performed at experienced centers in carefully selected cases.